Switch from HIV pills to long-acting monthly injections
This study looks at switching people with HIV from daily or regular oral medicine to long-acting injections (cabotegravir plus rilpivirine). It may help those who are well-controlled on current therapy who prefer injections and can safely take this combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign informed consent
- Have HIV-1 infection and be on HIV treatment pills right now
- Have an undetectable HIV viral load for the past 6 months
- Be willing to switch from oral medicine to the long-acting injections
- Not have past treatment failure or known major resistance to these drug types
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how people living with HIV feel after switching to a two-shot injection (Cabotegravir and Rilpivirine) given every two months. It collects your feedback on quality of life and symptoms to see how the new treatment works in real life.
This study looks at how people living with HIV feel (quality of life) and how well their virus is controlled after they finish a long-acting injectable treatment with cabotegravir and rilpivirine. It's a follow-up to see if this easier treatment helps people stay healthy and feel better.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
Hear when a new Patient Satisfaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.